奈达铂与紫杉醇联合同期放疗对中晚期宫颈癌的临床疗效分析  

Analysis of Clinical Efficacy of Nedaplatin, Paclitaxel combined with Concurrent Radiotherapy in Advanced Cervical Cancer

作　　者：张云[1] 朱勇[1] 李晓花[1] 杨哲[1] 张晓智[2] ZHANG Yun ZHU Yong LI Xiao-hua YANG Zhe ZHANG Xiao-zhi(Department of Radiotherapy, Baoji Central Hospital, Baoji, Shaanxi, 721008, China The First Aftiliated Hospital of Xi＇An Jiao Tong University, Xi＇an, Shaanxi, 710000, China)

机构地区：[1]宝鸡市中心医院放射治疗科,陕西宝鸡721008 [2]西安交通大学第一附属医院,陕西西安710000

出　　处：《现代生物医学进展》2017年第11期2137-2139,2161,共4页Progress in Modern Biomedicine

基　　金：宝鸡市卫生局科研项目(201308)

摘　　要：目的:探讨紫杉醇-奈达铂联合同期放疗治疗中晚期宫颈癌的临床疗效。方法:选择2012年1月~2013年12月62例中晚期宫颈癌患者,随机分成观察组和对照组,各31例,两组患者均行盆腔三维适型放疗+腔内后装放疗,观察组在此基础上同时再行奈达铂、紫杉醇全身化疗。结果:两组近期疗效比较,差异具有统计学意义(P<0.05)。两组患者不良反应主要表现为骨髓抑制和胃肠道反应。随访一年,两组患者一年生存率比较差异显著(P<0.05)。结论:本研究采用放疗联合紫杉醇+奈达铂化疗治疗中晚期宫颈癌有效率高,耐受性好,值得临床推广应用。Objective： To observe the clinical effect of paclitaxel-Nedaplatin combined with concurrent chemotherapy and radio- therapy on the treatment of advanced cervical cancer. Methods＂ 62 patients with advanced cervical cancer who were treated in our hospi- tal from January 2012 to December 2013 were selected and randomly divided into the observation group and the control group, with 31 cases in each group. All patients underwent pelvic irradiation and intracavitary radiation therapy, and the patients in the observation group were treated with nedaplatin and paclitaxel chemotherapy. Results： The differences in short-time curative effect of two groups were statistically significant （P〈0.05）; The main adverse reactions of two groups were bone marrow and gastrointestinal system response; The differences in one-year survival rate of two groups after one-year follow-up were statistically significant （P〈0.05）. Conclusion： Nedaplatin-paclitaxel combined with concurrent radiotherapy is efficient and tolerant in the treatment of advanced cervical cancer, and it is worthy of clinical application.

关 键 词：奈达铂 紫杉醇 中晚期宫颈癌 同步放化疗 

分 类 号：R737.33[医药卫生—肿瘤]